216 related articles for article (PubMed ID: 28442504)
21. MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer.
Chapman BV; Wald AI; Akhtar P; Munko AC; Xu J; Gibson SP; Grandis JR; Ferris RL; Khan SA
BMC Cancer; 2015 Nov; 15():861. PubMed ID: 26545583
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus in metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma.
Compton AM; Moore-Medlin T; Herman-Ferdinandez L; Clark C; Caldito GC; Wang XI; Thomas J; Abreo FW; Nathan CO
Otolaryngol Head Neck Surg; 2011 Jul; 145(1):51-7. PubMed ID: 21493313
[TBL] [Abstract][Full Text] [Related]
23. The expression of activin receptor-like kinase 1 among patients with head and neck cancer.
Chien CY; Chuang HC; Chen CH; Fang FM; Chen WC; Huang CC; Huang HY
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):965-73. PubMed ID: 23447486
[TBL] [Abstract][Full Text] [Related]
24. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival.
Haraf DJ; Nodzenski E; Brachman D; Mick R; Montag A; Graves D; Vokes EE; Weichselbaum RR
Clin Cancer Res; 1996 Apr; 2(4):755-62. PubMed ID: 9816227
[TBL] [Abstract][Full Text] [Related]
25. Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments.
Carrero I; Liu HC; Sikora AG; Milosavljevic A
Oncogene; 2019 May; 38(19):3551-3568. PubMed ID: 30655605
[TBL] [Abstract][Full Text] [Related]
26. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy.
Martin D; Rödel F; Balermpas P; Rödel C; Fokas E
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):221-230. PubMed ID: 28501560
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
28. Management of the "violated neck" in the era of chemoradiation.
Loyo M; Johnson JT; Westra WH; Chiosea SI; Gourin CG
Laryngoscope; 2011 Nov; 121(11):2349-58. PubMed ID: 21993776
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of T-lymphoma invasion and metastasis inducing factor 1 in squamous-cell carcinoma of the head and neck and its clinical significance.
Wang S; Li S; Yang X; Yang S; Liu S; Liu B; Liu J
Eur J Cancer; 2014 Jan; 50(2):379-87. PubMed ID: 24189000
[TBL] [Abstract][Full Text] [Related]
30. Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.
Rettig EM; Chung CH; Bishop JA; Howard JD; Sharma R; Li RJ; Douville C; Karchin R; Izumchenko E; Sidransky D; Koch W; Califano J; Agrawal N; Fakhry C
Cancer Prev Res (Phila); 2015 Apr; 8(4):287-95. PubMed ID: 25633867
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
32. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
33. Squamous cell carcinoma of head and neck: what internists should know.
Jung K; Narwal M; Min SY; Keam B; Kang H
Korean J Intern Med; 2020 Sep; 35(5):1031-1044. PubMed ID: 32663913
[TBL] [Abstract][Full Text] [Related]
34. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Mody MD; Gill HS; Saba NF
JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
[TBL] [Abstract][Full Text] [Related]
35. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
[TBL] [Abstract][Full Text] [Related]
36. Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations.
Wu SY; Yom SS
Curr Treat Options Oncol; 2019 Dec; 20(12):89. PubMed ID: 31797157
[TBL] [Abstract][Full Text] [Related]
37. HPV status and overall survival of patients with oropharyngeal squamous cell carcinoma--a retrospective study of a German head and neck cancer center.
Tahtali A; Hey C; Geissler C; Filman N; Diensthuber M; Leinung M; Stöver T; Wagenblast J
Anticancer Res; 2013 Aug; 33(8):3481-5. PubMed ID: 23898123
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma.
Sisk EA; Soltys SG; Zhu S; Fisher SG; Carey TE; Bradford CR
Head Neck; 2002 Sep; 24(9):841-9. PubMed ID: 12211048
[TBL] [Abstract][Full Text] [Related]
39. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.
Ganly I; Soutar DS; Brown R; Kaye SB
Br J Cancer; 2000 Jan; 82(2):392-8. PubMed ID: 10646894
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
